MIRA is developing a new molecular synthetic THC analog called MIRA1a, designed for the treatment of adult patients with anxiety and cognitive decline, typically associated with early-stage dementia.   MIRA’s initial focus will be a dual path: potentially winning in traditional pain and anxiety markets as well as the marijuana analog markets with a potentially safe and effective option if approved by the FDA.